Insider Transactions in Q1 2021 at Biocryst Pharmaceuticals Inc (BCRX)
Insider Transaction List (Q1 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 31
2021
|
Helen M. Thackray Chief R&D Officer |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+50.0%
|
-
|
|
Mar 18
2021
|
Michael L Jones Exec. Director, Finance - PAO |
BUY
Exercise of conversion of derivative security
|
Direct |
4,500
+45.69%
|
$13,500
$3.51 P/Share
|
|
Feb 26
2021
|
Steve Aselage Director |
BUY
Grant, award, or other acquisition
|
Direct |
927
+2.86%
|
$9,270
$10.78 P/Share
|
|
Feb 26
2021
|
Theresa Heggie Director |
BUY
Grant, award, or other acquisition
|
Direct |
463
+3.24%
|
$4,630
$10.78 P/Share
|
|
Feb 26
2021
|
Nancy J Hutson Director |
BUY
Grant, award, or other acquisition
|
Direct |
463
+0.71%
|
$4,630
$10.78 P/Share
|
|
Feb 26
2021
|
Robert Alexander Ingram Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,739
+2.27%
|
$17,390
$10.78 P/Share
|
|
Feb 22
2021
|
William P Sheridan Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
41,250
-78.24%
|
$453,750
$11.57 P/Share
|
|
Feb 22
2021
|
William P Sheridan Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
41,250
+43.89%
|
$165,000
$4.15 P/Share
|
|
Feb 19
2021
|
Yarlagadda S Babu Chief Discovery Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
22,431
-10.91%
|
$246,741
$11.53 P/Share
|
|
Feb 19
2021
|
Yarlagadda S Babu Chief Discovery Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+19.56%
|
$200,000
$4.15 P/Share
|